Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?
| Autor: | Meir Steiner, Adrienne Einarson, Gideon Koren, David C. Knoppert, Doreen Matsui |
|---|---|
| Rok vydání: | 2005 |
| Předmět: | |
| Zdroj: | Canadian Medical Association Journal. 172:1457-1459 |
| ISSN: | 1488-2329 0820-3946 |
| Popis: | 1Physicians were advised to taper the dosage of antidepressants in pregnant women during the last trimester so that the fetus receives no drug for at least 7–10 days before delivery. A month later, Health Canada followed suit; the Canadian advisory 2 similarly suggested that “Physicians may consider slowly decreasing the dose of these medications in the third trimester.” These advisories were based on “reports reveal[ing] that some newborns whose mothers took these medications during pregnancy have developed complications at birth.” 2 These complications were seen as consistent with withdrawal symptoms or a direct adverse effect by the antidepressant on the baby. We believe those recommendations are only partially evidence-based and may put the depressed mother-to-be and her baby at an unreasonable health risk. This paper presents a brief discussion of the pattern of neonatal symptoms observed after maternal use of selective serotonin or serotonin–norepinephrine reuptake inhibitors (SSRIs or SNRIs, respectively). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|